Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Solid Tumours 3Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Papillary renal cell carcinoma, sporadic 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × GSK 1363089 × Clear all
NCT00725712 2017-08-24

Study of GSK1363089 in Metastatic Gastric Cancer

GlaxoSmithKline

Phase 2 Completed
74 enrolled 22 charts
Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT02034097 2014-05-19

A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

GlaxoSmithKline

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡